全文获取类型
收费全文 | 3308篇 |
免费 | 163篇 |
国内免费 | 12篇 |
专业分类
耳鼻咽喉 | 46篇 |
儿科学 | 252篇 |
妇产科学 | 84篇 |
基础医学 | 404篇 |
口腔科学 | 48篇 |
临床医学 | 380篇 |
内科学 | 835篇 |
皮肤病学 | 30篇 |
神经病学 | 283篇 |
特种医学 | 68篇 |
外国民族医学 | 1篇 |
外科学 | 363篇 |
综合类 | 24篇 |
一般理论 | 1篇 |
预防医学 | 262篇 |
眼科学 | 40篇 |
药学 | 164篇 |
中国医学 | 4篇 |
肿瘤学 | 194篇 |
出版年
2022年 | 18篇 |
2021年 | 59篇 |
2020年 | 41篇 |
2019年 | 47篇 |
2018年 | 65篇 |
2017年 | 43篇 |
2016年 | 35篇 |
2015年 | 49篇 |
2014年 | 61篇 |
2013年 | 117篇 |
2012年 | 142篇 |
2011年 | 147篇 |
2010年 | 77篇 |
2009年 | 87篇 |
2008年 | 144篇 |
2007年 | 172篇 |
2006年 | 140篇 |
2005年 | 138篇 |
2004年 | 171篇 |
2003年 | 137篇 |
2002年 | 142篇 |
2001年 | 129篇 |
2000年 | 150篇 |
1999年 | 120篇 |
1998年 | 49篇 |
1997年 | 36篇 |
1996年 | 35篇 |
1995年 | 15篇 |
1994年 | 24篇 |
1993年 | 21篇 |
1992年 | 68篇 |
1991年 | 68篇 |
1990年 | 70篇 |
1989年 | 75篇 |
1988年 | 62篇 |
1987年 | 70篇 |
1986年 | 31篇 |
1985年 | 50篇 |
1984年 | 33篇 |
1983年 | 38篇 |
1982年 | 18篇 |
1981年 | 16篇 |
1979年 | 39篇 |
1978年 | 26篇 |
1977年 | 15篇 |
1976年 | 24篇 |
1974年 | 22篇 |
1973年 | 21篇 |
1972年 | 23篇 |
1971年 | 12篇 |
排序方式: 共有3483条查询结果,搜索用时 15 毫秒
51.
52.
P Morice S Camatte A Rey D Atallah C Lhommé P Pautier C Pomel J-F Coté C Haie-Meder P Duvillard D Castaigne 《Annals of oncology》2003,14(4):592-598
BACKGROUND: The aim of this study was to determine the prognostic factors for patients with advanced stage, low malignant potential ovarian tumour (LMPOT). PATIENTS AND METHODS: A retrospective review of 80 patients with serous LMPOT and peritoneal implants treated at or referred to our institution was carried out. RESULTS: Sixty-five patients had non-invasive implants. Fifteen patients had invasive implants. Twenty-nine patients had stage II and 51 patients had stage III disease. Three patients died of evolutive invasive disease and four of complications of treatment. The only prognostic factor of progression to 'evolutive invasive disease' is the pathologic subtype of peritoneal implants. The 5-year rates of evolutive invasive disease in patients with non-invasive implants and invasive implants were 2% and 31%, respectively (P <0.002). CONCLUSIONS: In this series, the only prognostic factor for patients with advanced stage borderline tumour is the type of peritoneal implant. More patients died of the treatment's complications than of the disease itself. The patients' prognosis with non-invasive implants seems to be excellent, and conservative management could be discussed in younger patients. 相似文献
53.
54.
P C Lara A Rey C Santana J L Afonso J M Diaz G J González R Apolinario 《Radiotherapy and oncology》1998,49(2):163-167
PURPOSE: To assess whether tumour proliferation as measured by Ki67 immunostaining has any predictive value for local control in bladder cancer patients treated by radiotherapy. PATIENTS AND METHODS: Fifty-five patients suffering from infiltrating bladder carcinoma recommended for radical radiotherapy (66 Gy/6-7 weeks) were included in this study. Paraffin-embedded pre-treatment tumour sections were stained with the Ki67 antibody. The percentage of Ki67-positive nuclei was correlated with established prognostic factors, local control and survival. RESULTS: The Ki67 index was not related to local control in our patients when the median was selected as the cut-off value. Patients with tumours with a very low (<27%) Ki67 index had better local control at 5 years (69%) than patients with tumours with greater (>27%) Ki67 expression indices (31.5%) (P<0.05; log-rank test). CONCLUSIONS: Ki67 immunostaining was a feasible method to estimate tumour proliferation. Patients with very low proliferating tumours seemed to achieve better local control after fractionated radiotherapy compared to other patients. Further studies are needed with a greater number of patients to accurately define the role of Ki67 expression in predicting tumour repopulation during fractionated radiotherapy. 相似文献
55.
McCusker EA Casse RF Graham SJ Williams DB Lazarus R 《The Medical journal of Australia》2000,173(4):187-190
OBJECTIVE: To estimate the prevalence of Huntington disease (HD) in New South Wales on Australian Census Day (6 August) 1996. DESIGN: Survey of records of the Huntington Disease Service and major hospitals, and of neurologists, psychiatrists, clinical geneticists and genetic counsellors. SUBJECTS AND SETTING: All patients in NSW who, on Census Day 1996, either had a definite diagnosis of HD (motor signs of chorea or ataxia and family history of HD or positive DNA test result) or would have had signs and later received a definite diagnosis (assessed 1 April 1997 to 1 July 1999). MAIN OUTCOME MEASURES: Prevalence (HD patients per 100,000 population); patient characteristics; year and basis of diagnosis. RESULTS: 380 patients with definite HD were identified, giving a prevalence of HD in NSW in 1996 of 6.29 per 100,000 population (95% CI, 5.68-6.96). A third of HD patients were aged 60 years or older. Diagnosis was confirmed by DNA testing for 171 patients (45%), including 30 (8%) with no recorded family history. Average numbers of new diagnoses per year were 11.8 (1984-1988), 21.8 (1989-1993) and 28.6 (1994-1998). Estimated number of people with a 50% risk of inheriting the HD mutation was 25.2 per 100,000 population. Estimated incidence of HD in 1996 was 0.65 per 100,000 population. CONCLUSIONS: Prevalence of HD in NSW is similar to estimated prevalence in other Australian and Western populations. Increasing numbers of cases are being diagnosed, and the 18 chronic care beds currently designated for HD patients in NSW are unlikely to be sufficient. 相似文献
56.
57.
Dominique Rey Maria-Patrizia Carrieri Bruno Spire Sandrine Loubière Pierre Dellamonica Hervé Gallais Gilles-Patrice Cassuto Jean-Albert Gastaut Yolande Obadia the MANIF Study Group 《Journal of urban health》2004,81(1):48-57
The last international consensus conference about hepatitis C virus (HCV) treatment emphasized the importance of treatment
for persons coinfected with HCV and human immunodeficiency virus (HIV). As liver biopsy precedes treatment, we aimed to identify
factors associated with the performance of liver biopsy among HIV-HCV coinfected drug users during a 5-year follow-up to study
their access to HCV treatment. Of the 296 patients followed in the HIV hospital departments of Nice and Marseilles and with
retrievable records about HCV diagnosis and care, 166 were eligible for analysis having had detectable HCV RNA at least once
during the study period. Overall, 45.2% of patients underwent liver biopsy during follow-up. Using proportional hazard models,
predictors of having had a liver biopsy were high social support, complete abstinence from drug injection, and lack of immunosuppression
as well as male gender, no history of multiple incarcerations, more recent onset of drug use, and an increase of liver enzyme
levels. These results suggest that specific efforts should be devoted to HIV-HCV coinfected drug users to assist with stabilizing
these patients to optimize their access to HCV care whenever possible.
The MANIF 2000 study group includes C. Boirot, A. D. Bouhnik, M. P. Carrieri, J. P. Cassuto, M. Chesney, P. Dellamonica, P.
Dujardin, S. Duran, J. G. Fuzibet, H. Gallais, J. A. Gastaut, G. Lepeu, D. A. Loundou, C. Marimoutou, D. Mechali, J. P. Moatti,
J. Moreau, M. Nègre, Y. Obadia, I. Poizot-Martin, C. Pradier, D. Rey, C. Rouzioux, A. Sobel, B. Spire, F. Trémolières, and
D. Vlahov. 相似文献
58.
59.
60.